BioCardia, Inc. (BCDA) Earnings Call Transcripts

BioCardia, Inc.'s Latest Earnings Call - Q1 FY2026

In Q1 2026, BioCardia, Inc. reported significant progress in its cardiac cell therapy programs, which could positively impact the stock. The company highlighted FDA breakthrough designation for its CardiAMP Heart Failure Trial and potential approval in Japan. Total expenses decreased to $2.3 million, with a net loss of $2.3 million, compared to $2.7 million in Q1 2025. Management did not provide specific revenue figures or updated earnings guidance.

Reported metrics

Guidance from management

Management did not provide specific forward guidance but indicated plans to complete transactions to fund ongoing trials and regulatory submissions.

What management said

Thank you, Gary. Our efforts advancing cell-based therapies for ischemic heart failure are showing important benefits for patients to the treatment of microvascular dysfunction. The positive regulatory interaction for approval in Japan is a transformative milestone. And we will continue to keep investors current on our progress towards submission and approval. On behalf of our entire BioCardia team, I thank all share...

What analysts pressed on

Analysts inquired about the regulatory process in Japan, specifically the additional work required for the shonin application and the timing of feedback from the agency. Concerns also included the integration of CardiAMP into Japan's treatment regimen.

Main topics on the call

• CardiAMP Heart Failure Trial Results — The CardiAMP Heart Failure Trial showed 'compelling signals of enhanced heart function' in treated patients. Management highlighted that treated patients did not experience negative heart remodeling, achieving statistica...
• Regulatory Progress in Japan — BioCardia received positive feedback from Japan's PMDA, which is inclined to accept CardiAMP data for regulatory submission. The company expects to submit a premarket application within 7 months.
• FDA Interactions — The FDA found the CardiAMP efficacy results 'intriguing' and encouraged completion of the ongoing CardiAMP HF II trial. The FDA agreed on a premarket approval pathway.
• Financial Performance — Total expenses decreased by $460,000 to $2.3 million, driven by reduced R&D expenses. The net loss was $2.3 million, a reduction from $2.7 million in Q1 2025.

Read the full BioCardia, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 21 BioCardia, Inc. earnings call transcripts on record, spanning March 29, 2022 to August 12, 2026. Based on this history, BioCardia, Inc. reports quarterly. The most recent call on file is dated August 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BCDA

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

21

First call

March 29, 2022

Most recent

August 12, 2026

Reporting cadence

quarterly